Sang-We Kim

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.

J. Neal, N. Pavlakis, P. Kundu, 2021 .

Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study.

M. Ahn, Dong-Wan Kim, J. Yang, 2017 .

P3.02a-013 Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial: Topic: ALK Clinical

Edward S. Kim, H. Groen, T. Clackson, 2017 .

Central nervous systemic efficacy of immune checkpoint inhibitors and concordance between intra/extracranial response in non-small cell lung cancer patients with brain metastasis

Jae Cheol Lee, H. Kim, Sang-We Kim, 2022, Journal of Cancer Research and Clinical Oncology.

BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity.

Sang-We Kim, Dae-Ho Lee, J. Huh, 2011, Leukemia research.

Both-sided intra-atrial intracardiac metastases as the initial presentation of testicular seminoma.

Sung Sook Lee, Yoon-Koo Kang, Sang-We Kim, 2007, Japanese journal of clinical oncology.

Safety and clinical activity of first-line durvalumab in advanced NSCLC: Updated results from a Phase 1/2 study.

P. Ascierto, M. Ahn, P. Ott, 2017 .

Angiosarcomas of the Bilateral Breast and Heart: Which One is the Primary Site?

Sang-We Kim, Dae-Ho Lee, C. Suh, 2012, The Korean journal of internal medicine.

Correction to: 33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018)

J. Taube, S. Jain, E. Schmidt, 2019, Journal of Immunotherapy for Cancer.

Integrin αvβ3 Induces HSP90 Inhibitor Resistance via FAK Activation in KRAS-Mutant Non–Small Cell Lung Cancer

Deokhoon Kim, E. Choi, Sang-We Kim, 2021, Cancer research and treatment.

Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.

N. Girard, K. O'Byrne, S. Ramalingam, 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

High-dose chemotherapy of cyclophosphamide, thiotepa and carboplatin (CTCb) followed by autologous stem-cell transplantation as a consolidation for breast cancer patients with 10 or more positive lymph nodes: a 5-year follow-up results.

Sung-Bae Kim, Sang-We Kim, Jin-Hee Ahn, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

Sagittal sinus thrombosis associated with transient free protein S deficiency after l-asparaginase treatment: case report and review of the literature

Sang-We Kim, Jae-Hong Lee, J. S. Kim, 2000, Clinical Neurology and Neurosurgery.

Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

K. O'Byrne, Keunchil Park, T. Mok, 2016, The Lancet. Oncology.

Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors

Keunchil Park, B. Cho, Sang-We Kim, 2021, JTO clinical and research reports.

T ransplantation for M etastatic Breast C ancer Patients: A 6- Y ear Follow -U p Result

Sung-Bae Kim, Sang-We Kim, Jin-Hee Ahn, 2009 .

High-dose chemotherapy of cyclophosphamide, thiotepa, and carboplatin (CTCb) followed by autologous stem-cell transplantation for metastatic breast cancer patients: a 6-year follow-up result.

Sung-Bae Kim, Sang-We Kim, Jin-Hee Ahn, 2005, Cancer research and treatment : official journal of Korean Cancer Association.

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.

Eunkyoung Kim, Yoon-Koo Kang, Sang-We Kim, 2003, Journal of Korean medical science.

Low prevalence of activated protein C resistance and coagulation factor V Arg506 to Gln mutation among Korean patients with deep vein thrombosis.

Sung-Bae Kim, Sang-We Kim, C. Suh, 1998, Journal of Korean medical science.

A Phase I and Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer

Yoon-Koo Kang, Sang-We Kim, Dae-Ho Lee, 2007, Clinical Cancer Research.

Comprehensive outcomes of on‐ and off‐antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis

H. Lee, Sang-We Kim, Y. Chung, 2016, Journal of medical virology.

First‐Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never‐Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non–Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study

M. Ahn, Keunchil Park, Chun-Ming Tsai, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

M. Ahn, Y. Ohe, H. Saka, 2015 .

ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC)

Jeffrey W. Scott, Keunchil Park, Dong-Wan Kim, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Edward S. Kim, H. Groen, E. Smit, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

E. Smit, Melissa L. Johnson, E. Felip, 2022, Journal of Clinical Oncology.

Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer

P. Jänne, Gregory Riely, E. Felip, 2021, JAMA oncology.

Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer

Melissa L. Johnson, P. Janne, Dong-Wan Kim, 2021, Cancer discovery.

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

P. Jänne, Melissa L. Johnson, Dong-Wan Kim, 2021 .

HSP90 inhibitor (NVP-AUY922) enhances the anti-cancer effect of BCL-2 inhibitor (ABT-737) in small cell lung cancer expressing BCL-2.

Sang-We Kim, Dae-Ho Lee, G. Koh, 2017, Cancer letters.

Safety, Pharmacokinetics, and Clinical Activity of Adavosertib in Combination with Chemotherapy in Asian Patients with Advanced Solid Tumors: Phase Ib Study

Keunchil Park, Y. Bang, Sang-We Kim, 2020, Targeted Oncology.

Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.

L. Sequist, M. Ahn, J. Yang, 2020, The Lancet. Oncology.

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Su Kyung Choi, M. Ahn, Sang-We Kim, 2021, Journal of Cancer Research and Clinical Oncology.

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Tae Yong Kim, Won Gu Kim, M. Ahn, 2018, Oncoimmunology.

Comparative effectiveness of bevacizumab plus cisplatin‐based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non‐squamous non‐small cell lung cancer patients applying real‐life outcomes

Stefan Walzer, Myung-Ju Ahn, M. Ahn, 2011, Asia-Pacific journal of clinical oncology.

ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI).

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study.

M. Ahn, E. Cho, Dong-Wan Kim, 2020 .

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.

J. Ahn, M. Ahn, E. Cho, 2019, The Lancet. Oncology.

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

S. Ou, Keunchil Park, E. Cho, 2021 .

Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer

David A. Smith, G. Scagliotti, Keunchil Park, 2016, Investigational New Drugs.

Real‐world utility of next‐generation sequencing for targeted gene analysis and its application to treatment in lung adenocarcinoma

S. Jang, Sang-We Kim, Dae-Ho Lee, 2021, Cancer medicine.

Genomic Alterations in the RB Pathway Indicate Prognostic Outcomes of Early-Stage Lung Adenocarcinoma

Daehyun Baek, S. Lee, Charles Lee, 2014, Clinical Cancer Research.

Recurrence-associated gene signature in patients with stage I non-small-cell lung cancer

Sang-We Kim, Dae-Ho Lee, Shinkyo Yoon, 2021, Scientific Reports.

First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.

Hyae-Young Kim, J. Ahn, M. Ahn, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.

Chia-Chi Lin, Tomonori Hirashima, Helen Mann, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-Line Erlotinib Therapy Until and Beyond Response Evaluation Criteria in Solid Tumors Progression in Asian Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer: The ASPIRATION Study.

M. Ahn, Keunchil Park, T. Mok, 2016, JAMA oncology.

The extended leukocyte differential count using the Cytodiff flow cytometric system reveals that higher CD16+ cytotoxic NK+T lymphocyte levels predict superior survival outcomes in patients with metastatic carcinoma

Sang-We Kim, M. Ryu, S. Jang, 2013, Cytometry. Part B, Clinical cytometry.

Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PD-L1) antibody, combined with gefitinib in patients (pts) with non-small-cell lung cancer (NSCLC).

D. Gibbons, Dong-Wan Kim, L. Chow, 2015 .

Clinical activity of ASP8273 in Asian patients with non‐small‐cell lung cancer with EGFR activating and T790M mutations

Keunchil Park, M. Fukuoka, K. Kiura, 2018, Cancer science.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2019, Future oncology.

Optimizing palliative chemotherapy for advanced invasive mucinous adenocarcinoma of the lung

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2021, BMC Cancer.

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2020, PloS one.

The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205.

Deokhoon Kim, Sang-We Kim, Dae-Ho Lee, 2019, American journal of cancer research.

EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation

Jae Cheol Lee, S. Jang, Sang-We Kim, 2014, Cancer Chemotherapy and Pharmacology.

Postoperative adjuvant chemotherapy and radiotherapy for stage II and III non-small cell lung cancer (NSCLC).

Sang‐wook Lee, Jong Hoon Kim, E. Choi, 2002, Lung cancer.

Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung Cancer

S. Hahn, Keunchil Park, Dong-Wan Kim, 2018, Cancer research and treatment : official journal of Korean Cancer Association.

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.

M. Tsuboi, R. Herbst, Yi-long Wu, 2020 .

Mutational Profiling of Malignant Mesothelioma Revealed Potential Therapeutic Targets in EGFR and NRAS

Deokhoon Kim, Tae Won Kim, S. Jang, 2018, Translational oncology.

The HSP90 inhibitor, NVP-AUY922, sensitizes KRAS-mutant non-small cell lung cancer with intrinsic resistance to MEK inhibitor, trametinib.

Ky-Youb Nam, Sang-We Kim, Dae-Ho Lee, 2016, Cancer letters.

Multiple resistant factors in lung cancer with primary resistance to EGFR-TK inhibitors confer poor survival.

Jae Cheol Lee, S. Jang, Sang-We Kim, 2015, Lung cancer.

ROS1 Receptor Tyrosine Kinase, a Druggable Target, is Frequently Overexpressed in Non-Small Cell Lung Carcinomas Via Genetic and Epigenetic Mechanisms

S. Jang, H. Lee, Sang-We Kim, 2012, Annals of Surgical Oncology.

Chemotherapy for advanced non-small-cell lung cancer patients with poor performance

Sang-We Kim, Kyu-pyo Kim, 2010, Expert review of clinical pharmacology.

A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Who Have Acquired Resistance to EGFR–Tyrosine Kinase Inhibitors

Hyae-Young Kim, Sang-We Kim, Y. Min, 2016, Cancer research and treatment : official journal of Korean Cancer Association.

Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer.

Deokhoon Kim, Sang-We Kim, Dae-Ho Lee, 2021, European journal of cancer.

Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis

Keunchil Park, Dong-Wan Kim, B. Cho, 2020, Current medical research and opinion.

Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer.

Joon-Oh Park, J. Ahn, M. Ahn, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of T790M Acquisition Between Patients Treated with Afatinib and Gefitinib as First-Line Therapy: Retrospective Propensity Score Matching Analysis

Jae Cheol Lee, Jae Hoon Kim, Sang-We Kim, 2019, Translational oncology.

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

Jae Cheol Lee, S. Jang, Sang-We Kim, 2013, BMC Cancer.

Weekly low dose paclitaxel and cisplatin as first-line chemotherapy for advanced non-small cell lung cancer.

S. D. Lee, Sang-We Kim, C. Suh, 2003, Lung cancer.

Phase II study of three-dimensional conformal radiotherapy and concurrent mitomycin-C, vinblastine, and cisplatin chemotherapy for Stage III locally advanced, unresectable, non-small-cell lung cancer.

Woo Sung Kim, Seung Do Ahn, Eun Kyung Choi, 2003, International journal of radiation oncology, biology, physics.

A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced/metastatic non-small-cell lung cancer

D. Gibbons, M. Roudier, Dong-Wan Kim, 2020, British Journal of Cancer.

Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea

M. Ahn, E. Cho, Dong-Wan Kim, 2020, Cancer research and treatment : official journal of Korean Cancer Association.

Impact of pseudoprogression and treatment beyond progression on outcome in patients with non-small cell lung cancer treated with immune checkpoint inhibitors

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2020, Oncoimmunology.

Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.

Edward S. Kim, H. Groen, E. Smit, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Clinical Activity, Tolerability, and Long-term Follow-up of Durvalumab in Patients With Advanced NSCLC.

D. Jäger, P. Ascierto, J. Nemunaitis, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression

K. O'Byrne, Keunchil Park, T. Mok, 2019, Journal of Cancer Research and Clinical Oncology.

BIW-8962, an Anti GM2 Ganglioside Monoclonal Antibody, in Previously Treated Advanced/Recurrent Lung Cancer: a Phase I/II Study

Keunchil Park, B. Cho, Sang-We Kim, 2018, Journal of Cancer Biology and Therapeutics.

Clinical and Testing Protocols for the Analysis of Epidermal Growth Factor Receptor Mutations in East Asian Patients with Non-small Cell Lung Cancer: A Combined Clinical-Molecular Pathological Approach

Jie Yang, M. Salto‐Tellez, J. Shih, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase 2 Study of the HSP‐90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non–Small Cell Lung Cancer

H. Groen, L. Sequist, E. Smit, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2022, Journal of Cancer Research and Clinical Oncology.

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non–Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

J. Ahn, M. Ahn, Keunchil Park, 2010, Clinical Cancer Research.

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)

M. Ahn, Dong-Wan Kim, B. Cho, 2016, Oncotarget.

Sang-We Kim, Dae-Ho Lee, Jin-Hee Ahn, 2015, BMC Cancer.

Gefitinib versus pemetrexed as second‐line treatment in patients with nonsmall cell lung cancer previously treated with platinum‐based chemotherapy (KCSG‐LU08‐01)

J. Ahn, M. Ahn, Keunchil Park, 2012, Cancer.

A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.

J. Ahn, M. Ahn, Keunchil Park, 2013, Lung cancer.

Non-Small Cell Lung Cancer with Resistance to EGFR-TKI Therapy: CT Characteristics of T790M Mutation-positive Cancer.

Jae Cheol Lee, Mi Young Kim, Sang-We Kim, 2018, Radiology.

A Randomized Double-Blind, Double-Dummy, Multicenter Trial of Azasetron versus Ondansetron to Evaluate Efficacy and Safety in the Prevention of Delayed Nausea and Vomiting Induced by Chemotherapy

Dong-Wan Kim, Sang-We Kim, H. Song, 2014, Cancer research and treatment : official journal of Korean Cancer Association.

Ramosetron Versus Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: A Multicenter, Randomized Phase III Trial, KCSG PC10-21.

J. Ahn, Sang-We Kim, Jin-Hyoung Kang, 2015, The oncologist.

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.

A. Drilon, T. Wilson, C. Chung, 2019, The Lancet. Oncology.

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

Melissa L. Johnson, K. Papadopoulos, Sang-We Kim, 2021 .

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer

Jae Cheol Lee, S. Jang, Sang-We Kim, 2013, BMC Cancer.

Clinical outcomes of nivolumab in patients with advanced non-small cell lung cancer in real-world practice, with an emphasis on hyper-progressive disease

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2020, Journal of Cancer Research and Clinical Oncology.

Feasibility, safety, and adequacy of research biopsies for cancer clinical trials at an academic medical center

Sang Min Lee, Tae Won Kim, S. Jang, 2019, PloS one.

P1.15-004 An Open-Label, Multitumor Phase II Basket Study of Olaparib and Durvalumab (MEDIOLA): Results in Patients with Relapsed SCLC

S. Domchek, Sang-We Kim, F. Barlesi, 2017 .

Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study.

M. Ahn, Haiyi Jiang, Dong-Wan Kim, 2016 .

Initial cytoreductive treatment with thalidomide plus bolus vincristine/doxorubicin and reduced dexamethasone followed by autologous stem cell transplantation for multiple myeloma

Sang-We Kim, Dae-Ho Lee, C. Suh, 2011, Investigational New Drugs.

The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.

Deokhoon Kim, Sang-We Kim, Dae-Ho Lee, 2017, Cancer letters.

Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.

Ying Cheng, Jin-Ji Yang, Jianxing He, 2019, The Lancet. Respiratory medicine.

Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non–small cell lung cancer (NSCLC): Efficacy updates and exploratory analysis of CNS ORR and overall ORR by baseline (BL) brain lesion status.

Edward S. Kim, H. Groen, E. Smit, 2018 .

Clinicopathologic significance of the K‐ras gene codon 12 point mutation in stomach cancer. An analysis of 140 cases

J S Lee, Sung-Bae Kim, Sang-We Kim, 1995, Cancer.

[18F]Fluorothymidine Positron Emission Tomography before and 7 Days after Gefitinib Treatment Predicts Response in Patients with Advanced Adenocarcinoma of the Lung

Jin-Sook Ryu, Dae Hyuk Moon, Seung Jun Oh, 2008, Clinical Cancer Research.

Renal Parenchymal Malakoplakia Presenting with Abscesses and Hepatic Extension Misdiagnosed as a Malignant Tumor: A Case Report

Sang-We Kim, Y. Kim, J. Woo, 2012 .

Peritoneal dissemination from malignant fibrous histiocytoma of the buttock: unusual metastases from a rare tumor.

Sang-We Kim, Dae-Ho Lee, H. Song, 2008, Gut and liver.

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2016, BMC Cancer.

Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.

Sang-We Kim, Dae-Ho Lee, J. Song, 2015, Clinical lung cancer.

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma

Sang-We Kim, Dae-Ho Lee, J. Huh, 2010, The Korean journal of internal medicine.

Ki‐67 expression as a prognostic factor in diffuse large B‐cell lymphoma patients treated with rituximab plus CHOP

Sang‐wook Lee, Sang-We Kim, Dae-Ho Lee, 2010, European journal of haematology.

Palliative treatment of inoperable malignant tracheobronchial obstruction: temporary stenting combined with radiation therapy and/or chemotherapy.

Ho-Young Song, J. Shin, Jin Hyoung Kim, 2009, AJR. American journal of roentgenology.

Pharmacologic Study of Belotecan in Combination with Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small Cell Lung Cancer

Yoon-Koo Kang, Sang-We Kim, Dae-Ho Lee, 2007 .

Bone metastasis in pulmonary sclerosing hemangioma

S. Jang, Sang-We Kim, M. K. Kim, 2015, The Korean journal of internal medicine.

Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies

T. Mitsudomi, M. Ahn, Dong-Wan Kim, 2019, Cancer research and treatment : official journal of Korean Cancer Association.

ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC).

Yi-long Wu, J. Rigas, Yuh-Min Chen, 2017 .

P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous

Keunchil Park, R. Dziadziuszko, Dong-Wan Kim, 2017 .

Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy.

Keunchil Park, E. Cho, Dong-Wan Kim, 2018, Lung cancer.

Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON

Jie Yang, L. Sequist, M. Ahn, 2022, Cancer discovery.

JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC).

R. Govindan, Keunchil Park, E. Cho, 2019, Journal of Clinical Oncology.

Prognosis of multi‐level N2‐positive non‐small cell lung cancer according to lymph node staging using endobronchial ultrasound‐transbronchial biopsy

Jae Cheol Lee, E. Choi, S. Jang, 2018, Thoracic cancer.

P-240 The number of tumor (+) N2 nodes as a prognostic factor in the patients with N2 disease non-small cell lung cancer after curative resection and postoperative thoracic radiotherapy

Sang‐wook Lee, E. Choi, S. D. Lee, 2003 .

Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type EGFR: First report of a phase III ATTENTION trial.

T. Mitsudomi, M. Ahn, Keunchil Park, 2014 .

Gefitinib with pemetrexed as first-line therapy in patients with advanced nonsquamous non-small cell lung cancer with activating epidermal growth factor receptor mutations.

Sang-We Kim, Dae-Ho Lee, Shinkyo Yoon, 2017, Annals of translational medicine.

Avelumab (anti–PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101.

D. Chakrabarti, A. Shaw, E. Felip, 2018 .

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): First report of efficacy and safety from a pivotal randomized phase (ph) 2 trial (ALTA).

Edward S. Kim, H. Groen, E. Smit, 2016 .

Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2021, Translational lung cancer research.

Patient attitudes towards chemotherapy as assessed by patient versus physician: a prospective observational study in advanced non-small cell lung cancer.

D. Chu, H. Kuo, Sang-We Kim, 2007, Lung cancer.

FDG-PET as a Potential Tool for Selecting Patients with Advanced Non–Small Cell Lung Cancer Who May Be Spared Maintenance Therapy after First-Line Chemotherapy

Sang-We Kim, Dae-Ho Lee, C. Suh, 2011, Clinical Cancer Research.

P1.01-070 BIW-8962, an Anti-GM2 Ganglioside Monoclonal Antibody, in Advanced/Recurrent Lung Cancer: A Phase I/II Study

Keunchil Park, Sang-We Kim, Dae-Ho Lee, 2017 .

Olaparib and durvalumab in patients with relapsed small cell lung cancer (MEDIOLA): An open-label, multicenter, phase 1/2, basket study.

S. Domchek, Sang-We Kim, M. D. de Jonge, 2023, Lung cancer.

Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

Gregory Riely, E. Felip, P. Janne, 2021 .

A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors.

J. Ahn, M. Ahn, E. Cho, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

OA05.03 Safety and Clinical Activity of Adoptive Cell Transfer Using Tumor Infiltrating Lymphocytes (TIL) Combined with Nivolumab in NSCLC

Sang-We Kim, E. Haura, J. Teer, 2018, Journal of Thoracic Oncology.

A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by ( 18 F)fluorothymidine-

Sang-We Kim, Jin-Hee Ahn, E. J. Kim, 2013 .

Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials

J. Shih, M. Kudo, Sang-We Kim, 2018, Journal of global oncology.

Postoperative radiation therapy following the incomplete resection of a non-small cell lung cancer

Sang‐wook Lee, Jong Hoon Kim, E. Choi, 2014, Radiation oncology journal.

Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC).

H. Groen, L. Sequist, E. Smit, 2012 .

Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.

K. O'Byrne, S. Ramalingam, M. Hellmann, 2020 .

Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study.

P. Postmus, Keunchil Park, R. Dziadziuszko, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Abstract CT031: Updated efficacy and safety profile of durvalumab monotherapy in urothelial carcinoma

T. Powles, M. Ahn, M. Maio, 2018, Clinical Trials.

Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

N. Girard, Keunchil Park, Dong-Wan Kim, 2020 .

First-line afatinib (A) vs gefitinib (G) for patients (pts) with EGFR mutation positive (EGFRm+) NSCLC (LUX-Lung 7): Patient-reported outcomes (PROs) and impact of dose modifications on efficacy and adverse events (AEs).

K. O'Byrne, Keunchil Park, T. Mok, 2016 .

Erlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II study.

Sang-We Kim, Dae-Ho Lee, C. Suh, 2011, Anticancer research.

Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis

Keunchil Park, Dong-Wan Kim, B. Cho, 2022, Cancer research and treatment.

Optimal Definition of Oligometastasis Showing Survival Benefits of Local Therapies during Tyrosine Kinase Inhibitor Treatment

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2022, Cancer research and treatment.

Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity

S. Sleijfer, E. Felip, J. Schellens, 2017, Clinical Cancer Research.

Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2016, BMC Cancer.

Updated safety and clinical activity of durvalumab monotherapy in previously treated patients with stage IIIB/IV NSCLC.

M. Ahn, N. Segal, A. Gupta, 2017 .

Safety and clinical activity of durvalumab (MEDI4736), an anti-PD-L1 antibody, in treatment-naïve patients with advanced non‒small-cell lung cancer.

D. Jäger, H. Wakelee, S. Ou, 2016 .

First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

J. Desai, Dong-Wan Kim, J. Bendell, 2023, Cancer Immunology, Immunotherapy.

The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study

Sung-Bae Kim, Tae Won Kim, Sang-We Kim, 2021, Cancer Medicine.

Lazertinib versus Gefitinib as First-line Treatment for EGFR-mutated Locally Advanced or Metastatic NSCLC: LASER301 Korean Subset.

M. Ahn, E. Cho, Dong-Wan Kim, 2023, Cancer research and treatment.

Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer

Yeon-Hee Park, J. Choi, Sang-We Kim, 2023, Nature Cancer.

Three-arm randomised controlled phase 2 study comparing pemetrexed and erlotinib to either pemetrexed or erlotinib alone as second-line treatment for never-smokers with non-squamous non-small cell lung cancer.

B. Han, Sang-We Kim, Dae-Ho Lee, 2013, European journal of cancer.

A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors

L. Sequist, M. Ahn, J. Yang, 2019, SSRN Electronic Journal.

False-Positive Hypermetabolic Lesions on Post-Treatment PET-CT after Influenza Vaccination

Sang-We Kim, Dae-Ho Lee, C. Suh, 2011, The Korean journal of internal medicine.

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Abidemi K. Adeniji, J. Riess, E. Felip, 2022, Lung cancer.

A Phase II Study of Erlotinib as a First-Line Therapy for Patients with Non—Small-Cell Lung Cancer with Favorable Clinical Predictors

E. Cho, Sang-We Kim, Heung Tae Kim, 2008 .

CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFRm Non-Small-Cell Lung Cancer: A Brief Report.

Keunchil Park, G. Kar, D. Camidge, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

P3.04-23 Phase 1b/2 Study to Evaluate Novel Combinations With Oleclumab (MEDI9447) in Previously Treated Advanced EGFRm NSCLC

N. Rizvi, D. Camidge, Dong-Wan Kim, 2018, Journal of Thoracic Oncology.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea.

J. Ahn, M. Ahn, Keunchil Park, 2018, Lung cancer.

Symptom experiences and health-related quality of life among non-small cell lung cancer patients participating in clinical trials.

Sang-We Kim, E. Oh, Kyunghwa Lee, 2019, Journal of clinical nursing.

Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2014, The oncologist.

Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR.

J. Ahn, M. Ahn, Keunchil Park, 2015, The Oncologist.

Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).

L. Livi, E. Felip, P. Ward, 2023, Journal of Clinical Oncology.

Preliminary Phase II results of a multicenter, open-label study of nazartinib (EGF816) in adult patients with treatment-naïve EGFR-mutant non-small cell lung cancer (NSCLC).

L. Sequist, E. Smit, E. Felip, 2018 .

Intracranial and systemic efficacy of repotrectinib in advanced ROS1 fusion-positive (ROS1+) non-small cell lung cancer (NSCLC) and central nervous system metastases (CNS mets) in the phase 1/2 TRIDENT-1.

C. Dooms, A. Drilon, E. Felip, 2023, Journal of Clinical Oncology.

Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases.

J. Ahn, M. Ahn, Dong-Wan Kim, 2017 .

Brigatinib (BRG) in patients (pts) with crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC) and brain metastases in the pivotal randomized phase 2 ALTA trial.

S. Gettinger, S. Ou, M. Ahn, 2017 .

Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer

Tae Yong Kim, Won Gu Kim, M. Ahn, 2018, Oncoimmunology.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

P. Jänne, M. Ranson, M. Ahn, 2015, The New England journal of medicine.

Efficacy of lorlatinib in treatment-naive patients with ALK-positive advanced non-small cell lung cancer in relation to EML4::ALK variant type and ALK with or without TP53 mutations.

A. Shaw, J. Jassem, Sang-We Kim, 2023, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with recurrent non-small cell lung cancer after definitive concurrent chemoradiation or radiotherapy

Jae Cheol Lee, Sang-We Kim, Dae-Ho Lee, 2022, Journal of Cancer Research and Clinical Oncology.

YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results.

J. Ahn, M. Ahn, E. Cho, 2018 .

A Prospective Single Arm Phase I/II Study: Consolidative Ipilimumab and Nivolumab with Thoracic Radiotherapy after Platinum Based Chemotherapy for Patients with Extensive-Stage Small Cell Lung Cancer

M. Schell, K. Latifi, T. Dilling, 2019, International Journal of Radiation Oncology*Biology*Physics.

Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.

Sang-We Kim, Dae-Ho Lee, C. Suh, 2009, Lung cancer.

Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

Jie Yang, P. Jänne, E. Smit, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The prophylactic use of lamivudine can maintain dose-intensity of adriamycin in hepatitis-B surface antigen (HBs Ag)-positive patients with Non-Hodgkin's lymphoma who receive cytotoxic chemotherapy.

Eunkyoung Kim, Yoon-Koo Kang, Sang-We Kim, 2003, Journal of Korean medical science.

Sang-We Kim, M. Ryu, S. Jang, 2013, Cytometry. Part B, Clinical cytometry.

Phase I Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, Administered Daily in Patients With Advanced Solid Tumors

Yoon-Koo Kang, Sang-We Kim, T. Werner, 2021 .

Updated overall survival and safety profile of durvalumab monotherapy in advanced NSCLC.

J. Nemunaitis, S. Ou, M. Ahn, 2018 .

Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial

S. Ou, Keunchil Park, Dong-Wan Kim, 2023, Nature Medicine.